Cystic fibrosis (CF) affects about 70,000 children and adults worldwide1. Currently, there is no cure for CF. Our best defenses against this disease are prevention and early diagnosis.
Next-generation sequencing (NGS) provides visibility into the cystic fibrosis transmembrane conductance regulator (CFTR) gene for increased clarity in molecular CF testing. Ultimately, this information can be used to make informed family planning decisions and choose optimized treatments, leading to a better quality of life.
The MiSeqDx System is the first FDA-cleared in vitro diagnostic (IVD) NGS platform offering a complete solution for accurate, comprehensive CF testing. One platform, the MiSeqDx instrument, runs both the MiSeqDx Cystic Fibrosis 139-Variant Assay and the MiSeqDx Cystic Fibrosis Clinical Sequencing Assay, streamlining the laboratory workflow and increasing operational efficiency.
* Number of samples passing QC metrics on the first attempt
† Wide adoption in the sequencing community as demonstrated by the number of publications in the PubMed database